Stockreport

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants wi...

BioAge Labs, Inc.  (BIOA) 
Last bioage labs, inc. earnings: 8/3 07:00 am Check Earnings Report
US:NYSE Investor Relations: investor.bio-amber.com
PDF First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-1 [Read more]